2026/04/13 更新

写真a

ナカヤ ミチオ
仲矢 道雄
NAKAYA Michio
所属
環境医学研究所 生体適応・防御研究部門 教授
大学院担当
大学院医学系研究科
職名
教授
 

論文 3

  1. In Vivo Retroviral Transduction of Cardiac Myofibroblasts Using Intramyocardial Injection Immediately Post-myocardial Infarction Open Access

    Ono, S; Watanabe, H; Horii, Y; Nakaya, M

    BIO-PROTOCOL   15 巻 ( 22 ) 頁: e5500   2025年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Bio Protocol  

    Following myocardial infarction (MI), myocardial cells undergo cell death, and the necrotic region is replaced by extracellular matrix (ECM) proteins such as collagens. Myofibroblasts are responsible for producing these ECM proteins. Cardiac myofibroblasts are differentiated from resident fibroblasts in response to inflammation. To date, genetically modified mice driven by the Periostin promoter and adeno-associated virus 9 (AAV9) carrying the Periostin promoter have been used for gene transfer into cardiac myofibroblasts. However, these methods require multiple steps and are time-consuming and expensive. Therefore, we developed a method for delivering genes into cardiac myofibroblasts using retroviruses. Specifically, the DNA of the target gene was transfected into Plat-E cells, which are packaging cells, to generate retroviruses. The virus-containing supernatant was then harvested, and the viruses were pelleted by centrifugation and suspended in PBS-containing polybrene. Subsequently, permanent occlusion of the left coronary artery was performed, and 20 μL of viral solution was immediately administered using a 29G needle at a position 1–2 mm below the ligation site in the heart of mice maintained in an open chest state. Using this method, we were able to introduce genes into the myofibroblasts of interest surrounding the MI site.

    DOI: 10.21769/BioProtoc.5500

    Open Access

    Web of Science

    Scopus

    PubMed

  2. 機械的刺激による筋線維芽細胞の分化 Open Access

    三重野 博貴, 仲矢 道雄

    日本薬理学雑誌   160 巻 ( 3 ) 頁: 221 - 221   2025年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:公益社団法人 日本薬理学会  

    DOI: 10.1254/fpj.25016

    Open Access

    Scopus

    PubMed

    CiNii Research

  3. Elevated PRELP expression in heart and liver fibrosis promotes collagen production Open Access

    Yamauchi, Y; Mieno, H; Suetsugu, H; Watanabe, H; Nakaya, M

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   734 巻   頁: 150785   2024年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Biochemical and Biophysical Research Communications  

    Fibrosis results from the excessive production of extracellular matrix proteins by myofibroblasts. It has recently been reported that in the heart, myofibroblasts develop chondrocyte-like properties following myocardial infarction as fibrosis progresses and tissues stiffen. However, the nature of these chondrocyte-like myofibroblasts remains unclear. In this study, we found that the expression of the proline- and arginine-rich end leucine-rich repeat protein (PRELP) was upregulated in hearts and livers stiffened by fibrosis with chronic inflammation. Moreover, we established that Prelp was specifically expressed in chondrocyte-like myofibroblasts. Prelp expression was found to be regulated by the transcription factor SOX9, and in cardiac and liver myofibroblasts, Prelp-knockdown was observed to reduce collagen expression. These findings reveal that PRELP is specifically expressed in chondrocyte-like myofibroblasts and that it promotes collagen production. PRELP could thus serve as a novel therapeutic target for treating fibrosis.

    DOI: 10.1016/j.bbrc.2024.150785

    Open Access

    Web of Science

    Scopus

    PubMed

科研費 2

  1. 高線維化能の筋線維芽細胞亜集団を規定し、かつ線維化を促進する受容体の解析

    研究課題/研究課題番号:26K02168  2026年4月 - 2029年3月

    科学研究費助成事業  基盤研究(B)

    仲矢 道雄

      詳細を見る

    担当区分:研究代表者 

    配分額:18200000円 ( 直接経費:14000000円 、 間接経費:4200000円 )

  2. 新規筋線維芽細胞亜集団の運命解析とそれに基づく線維化治療法の開発

    研究課題/研究課題番号:25K22523  2025年6月 - 2027年3月

    科学研究費助成事業  挑戦的研究(萌芽)

    仲矢 道雄

      詳細を見る

    担当区分:研究代表者 

    配分額:6500000円 ( 直接経費:5000000円 、 間接経費:1500000円 )

    線維化は、筋線維芽細胞によるコラーゲンなどの細胞外マトリックスの過剰産生・蓄積によって生じ、慢性疾患やがんの進展に関与するが、決定的な治療法は存在しない。筋線維芽細胞は炎症を契機に線維芽細胞から分化するが、その寿命や性質の変化は未解明である。我々は、あるタンパク質の発現によってコラーゲン産生能の高い筋線維芽細胞亜集団が規定されることを見出した。そこでこの筋線維芽細胞亜集団の運命解析を行い、新たな線維化治療法開発の基盤構築を目指す。